1. At a Glance – Blink and You’ll Miss It
Sharda Cropchem just reported Q3 FY26 numbers that look like a Bollywood comeback montage. Quarterly sales came in at ₹1,289 Cr, up 38.7% YoY, while PAT jumped 366% YoY to ₹145 Cr. Yes, that’s not a typo. The stock is trading at ₹985, market cap ₹8,884 Cr, with a P/E of 15.7x, while the industry median is chilling at ~28.6x.
This is an asset-light, zero-debt-ish, export-heavy agrochemical player operating across 80+ countries, with Europe and NAFTA paying most of the bills. After two ugly years of inventory destocking, channel pain, and pricing pressure, Sharda seems to be saying: “Bas ho gaya, ab recovery dekh.”
ROCE stands at 16.5%, ROE 12.6%, dividend yield 0.91%, and interim dividend just announced at ₹6/share. But before you start celebrating like it’s FY22 again — remember, this company has given investors both champagne years and nimbu-paani years.
So the real question: Is this a sustainable recovery or just one strong quarter with good optics? Let’s open the books, auditor-style.
2. Introduction – Export King with a Mood Swing Problem
Sharda Cropchem is not your typical Indian agrochemical manufacturer with massive factories and smokestacks. It is more like a passport-heavy trader with a PhD in registrations. The company identifies off-patent generic molecules, files registrations across global markets, and outsources manufacturing to third parties. The result? Low capex on plants, high spend on dossiers, and global scalability.
This model worked beautifully during FY18–FY22, when global agro demand was strong and distributors were hoarding inventory like toilet paper in COVID. Then FY23–FY25 happened — inventory destocking, pricing pressure, weak LATAM demand, and Europe being Europe.
Margins collapsed, ROCE dipped to single digits in FY24, profits evaporated, and the stock got hammered from ₹1,100+ to ~₹440 at the lows.
Fast forward to FY26, and suddenly:
- Inventory cycle is normalising
- Volume recovery is visible
- Pricing has stopped bleeding
- Europe
